Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.
Giuditta Illuzzi, Alessandro Galbiati, Anna Dominika Staniszewska, Robert Hanson, Chrysiis Michaloglou, Sophie L. Cooke, Karolina Uznańska, Maja Białecka, Kamil J. Solarczyk, Harveer Dev, Charles E. Massie, Mark Robert Albertella, Elisabetta Leo, Josep V. Forment, Mark J. O’Connor
This study shows that combining androgen receptor inhibitors with PARP inhibitors enhances DNA damage in prostate cancer models, independent of BRCA mutations, by increasing double-strand breaks and micronuclei formation.
NAR Cancer · Oct 7, 2025Peer-reviewedCancer Biology